The Effect of Histamine H1 Receptor Antagonist, Clemastin, on PACAP38 Induced Headache in Migraine Patients
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effects of antihistamine (Clemastin) on
migraines triggered by pituitary adenylate cyclase activating peptide-38 (PACAP38) as well as
on biochemical markers for mast cell degranulation in migraine patients. Also, to investigate
the occurrence of migraine in migraine patients after infusion of PACAP38 in lower dosages
than previously investigated. As this has never been done before it is unknown how a lower
dose of PACAP38 will affect 1) the incidence of migraine attacks, 2) the accompanying
symptoms, 3) head pain characteristics, and 4) debut and duration of migraine attacks.
Our three hypotheses are:
1. Pre-treatment with Clemastin reduces PACAP38 sensitivity and inhibits development of
migraine in migraine patients.
2. Clemastin inhibits the increase in plasma concentration of TNF-alpha, histamine and
tryptase after PACAP38-infusion.
3. PACAP38 in lower dosages (4, 6 and 8 pmol/kg/min) induces migraine in migraine patients.